GLOW combines GHK-Cu, BPC-157 and TB-500 in one peptide blend. GHK-Cu has been investigated for collagen production and tissue remodelling, while BPC-157 research includes tissue repair models. TB-500, a sythentic form of Thymosin Beta-4 is a natural protein found in the body that helps with tissue repair, reducing inflammation and improving flexibility.
Already have an account? Log in
SEQUORA GLOW Blend 70mg is a three-compound Peptide blend containing 50mg GHK-Cu, 10mg BPC-157 and 10mg TB-500. Available in vial and prefilled pen formats, GLOW’s research explores processes involved in tissue repair and collagen production, including skin, tendon and intestinal research models.
The 70mg figure indicates the total stated content across all four compounds, not the concentration or amount delivered per withdrawal. Review the specifications for your selected format.
All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.
SEQUORA GLOW is a product name for an injectable blend of three peptides: GHK-Cu, BPC-157, and TB-500. The name GLOW is commonly used by most clinics and vendors for the same trio, and each ingredient is a separate compound with its own research history.
KLOW is GLOW plus KPV, which makes it a four-peptide blend. KPV is a short peptide that the FDA lists among substances nominated for compounding, and its regulatory story is covered in the status section below. The other three ingredients are identical in both products.
KPV’s main benefit is inflammation battling properties, so if this isn’t something you’re looking to treat or suffer with, then GLOW will have the same benefits as KLOW at a smaller price point.
GLOW’s characteristic blue colour comes from GHK-Cu, the copper peptide in the blend. GHK is a three-amino-acid peptide that binds to a copper ion. This complex absorbs certain wavelengths of visible light, giving it its blue appearance.
SEQUORA GLOW contains 50mg of GHK-Cu within its 70mg peptide blend, making it approximately 71% of the stated peptide content. BPC-157 and TB-500 do not normally contribute a blue colour.
The freeze-dried powder may appear pale blue, while a dissolved solution can look clear blue. Its appearance varies with concentration, formulation and lighting.
Side effects come from clinical trials and patient studies and are not confirmed medically. Injection site reactions are the most frequent as that’s a normal reaction to GHK-Cu and mild sensitivity or soreness around the injection site.
Product information, handling and safety
What Temperature should I store my GLOW at?
What are the best practices for using GLOW safely?
The documentation behind GLOW and it's uses
GLOW combines GHK-Cu, BPC-157 and TB-500 in one peptide blend. GHK-Cu has been investigated for collagen production and tissue remodelling, while BPC-157 research includes tissue repair models. TB-500, a sythentic form of Thymosin Beta-4 is a natural protein found in the body that helps with tissue repair, reducing inflammation and improving flexibility.
Upon delivery store in a refridgerator between 2-8°C.
Avoid dropping or heavy-handling of your GLOW Blend.
Please do not freeze your SEQUORA GLOW Pen as this can compromise the individual peptides.
Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.
Your SEQUORA GLOW Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.
SEQUORA GLOW Blend Vials before reconstitution can last up to 4 years at -5°C
GLOW can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.
Before handling your GLOW, needles or injection material, ensure your research area is clean and clear.
Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.
If at any point the cleanliness of your injection or environment is compromised, restart this step.
Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.
Before using your SEQUORA GLOW Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.
If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.
Ensure that your needle tips, syringes and vials are safely disposed of post-use.
This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.
Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.
GLOW combines GHK-Cu, BPC-157 and TB-500. Its safety profile as a combined injectable product has not been established. Human safety information for its ingredients is limited and individual user reports cannot reliably identify which ingredient caused a reaction.
Reported reactions and their limitations
Individual user experiences
Online accounts involving GLOW and related blends describe injection-site stinging, burning, soreness or lumps. These are unverified personal reports, not established clinical side effects. Product identity, concentration, sterility and other substances used may be uncertain.
Other important risks and uncertainties
Combining GHK-Cu, BPC-157 and TB-500 introduces unanswered questions about compatibility, stability, interactions and long-term effects. Evidence about one ingredient does not establish the safety of the blend.
Injection introduces additional risks, including infection, abscess formation and tissue injury. Unexpected reactions may also relate to the diluent, contamination, incorrect concentration or administration technique.
When to seek medical advice
Stop use and seek prompt medical advice for persistent burning, worsening pain, a new rash or other unexplained symptoms. Increasing redness, warmth, swelling, discharge or fever requires prompt assessment for possible infection.
Symptoms requiring emergency help
Call 999 for difficulty breathing, sudden swelling of the lips, tongue or throat, chest pain or collapse. Do not assume breathing problems or a racing heartbeat are simply anxiety or a normal response to the product.
About this information
This summary distinguishes regulatory safety concerns, limited adverse-event reports and unverified personal experiences. These do not establish the frequency or cause of reactions to GLOW and are not verified adverse reactions to SEQUORA products. This information does not establish suitability for human use or replace medical advice.
No mitigation protocol has been established that makes the GLOW blend safe. The following measures address reported injection-related problems and other potential risks. They are not a recommendation to continue using a product that causes symptoms.
Injection-site burning, soreness or lumps
Rash or suspected allergic reactions
Breathing discomfort, palpitations or feeling faint
Stop use and seek medical assessment. Do not manage these symptoms solely by changing the dose, dilution or timing. Call 999 for difficulty breathing, chest pain, collapse or palpitations accompanied by breathlessness or fainting.
Avoid unproven corrective measures
Reduce contamination and preparation errors
Keep a record of any reaction
About this information
Personal reports can identify concerns worth investigating, but they cannot establish a safe dose or an effective mitigation strategy. These measures do not validate GLOW’s compatibility, stability, sterility or suitability for injection and do not replace individual medical advice.
The GLOW Blend has a typical structure of 4-6 weeks “on-cycle” and 2-4 weeks “off-cycle”, this is mainly due to the copper accumulation from GHK-Cu.
GLOW Should be injected DAILY. Always confirm the pens strength before each administration.
Calculation basis: 70 mg total blend in a final volume of 3 ml, with 0.01 ml delivered per pen dial unit. “Dose” shows the nominal amount; “Total Dose” shows the calculated amount at the listed setting.
| Dose | Phase | 70mg Pen Dial Setting | Total Dose | Breakdown of doses |
|---|---|---|---|---|
| 1.75 mg | Weeks 1–2 | 8 | ≈1.867 mg total blend | GHK-Cu: ≈1.333 mg / BPC-157: ≈267 mcg / TB-500: ≈267 mcg |
| 3.5 mg | Weeks 3–4 | 15 | 3.5 mg total blend | GHK-Cu: 2.5 mg / BPC-157: 500 mcg / TB-500: 500 mcg |
| 5.25 mg | Weeks 5–8 | 23 | ≈5.367 mg total blend | GHK-Cu: ≈3.833 mg / BPC-157: ≈767 mcg / TB-500: ≈767 mcg |
| 3.5 mg | Weeks 9–12 (taper) | 15 | 3.5 mg total blend | GHK-Cu: 2.5 mg / BPC-157: 500 mcg / TB-500: 500 mcg |
Understanding the figures
Doses are expressed in milligrams per daily administration. Each numbered dial of the pen delivers 0.01ml of liquid or 1 Unit. The SEQUORA 70mg GLOW Pen contains 3ml of reconstituted GLOW meaning every 1 dial = Approximately 0.2333 mg of GLOW Blend (166.7 mcg of GHK-Cu / 33.3 mcg each of BPC-157 and TB-500).